Gilead Sciences announced new findings Friday that its antiviral drug remdesivir reduced the risk of death for severely sick coronavirus patients by 62% compared with standard care alone.
The company said its analysis also found that remdesivir treatment was associated with “significantly improved clinical recovery.” The findings are being presented at the Virtual Covid-19 Conference as part of the 23rd International AIDS Conference, the company said.
Shares of Gilead rose more than 2% Friday on the news.
Gilead said it analyzed data from 312 patients enrolled in its phase three trial and compared it with that of 818 patients in “a real-world retrospective cohort” with similar characteristics and disease severity who received standard care alone during the same time period as the phase three trial.
“While not as vigorous as a randomized controlled trial, this analysis importantly draws from a realworld setting and serves as an important adjunct to clinical trial data, adding to our collective understanding of this virus and reflecting the extraordinary pace of the ongoing pandemic,” Dr. Susan Olender of Columbia University Irving Medical Center said in a statement.
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.
For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology
For the latest health news from BBC, Please click here
The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources
For the number of cases and epidemiology in each country go to: WorldOMeters
DAILY NEW CASES AND DEATHS IN US, CDC SITE